retatrutide where to get it Lilly Prepares for FDA Filing Following Additional Phase 3 Data in Diabetes, CVD Triple G 8 mg

6 min walk test is a strong independent predictor of death in outpatients with heart failure

Some genetic profiles respond faster to appetite suppression (suggesting an earlier meal-time dose works well), while others show delayed but sustained responses (making a consistent injection day more important than exact meal timing)

N Engl J Med 2023;388:117-27.ArticlePubMed 50

Tirzepatide India: Lilly and Cipla Expand Access to Advanced Diabetes and Obesity Care India may soon see wider access to Tirzepatide, one of the most potent therapies approved for use in people with type 2 diabetes and chronic weight management, as Eli Lilly and Company India recently signed an agreement with Cipla Limited, allowing the pharmaceutical company Cipla to distribute and promote the drug under a second brand name Yurpeak throughout India